UB Paderborn / Katalog / Suche / in CDI

1 – 23 von 23

Sortiert nach

The Bruton Tyrosine Kinase (BTK) Inhibitor Acalabrutinib Demonstrates Potent On-Target Effects and Efficacy in Two Mouse Models of Chronic Lymphocytic Leukemia

Clinical cancer research, 2017-06, Vol.23 (11), p.2831-2841

2017

Link zum Volltext

Verfügbarkeit prüfen

Disruption of in vivo Chronic Lymphocytic Leukemia Tumor-Microenvironment Interactions by Ibrutinib--Findings from an Investigator-Initiated Phase II Study

Clinical cancer research, 2016-04, Vol.22 (7), p.1572-1582

2016

Link zum Volltext

Verfügbarkeit prüfen

Interactions between Ibrutinib and Anti-CD20 Antibodies: Competing Effects on the Outcome of Combination Therapy

Clinical cancer research, 2016-01, Vol.22 (1), p.86-95

2016

Link zum Volltext

Verfügbarkeit prüfen

Combined BTK and PI3Kδ Inhibition with Acalabrutinib and ACP-319 Improves Survival and Tumor Control in CLL Mouse Model

Clinical cancer research, 2017-10, Vol.23 (19), p.5814-5823

2017

Link zum Volltext

Verfügbarkeit prüfen

Unique Cell Surface Expression of Receptor Tyrosine Kinase ROR1 in Human B-Cell Chronic Lymphocytic Leukemia

Clinical cancer research, 2008-01, Vol.14 (2), p.396-404

2008

Link zum Volltext

Verfügbarkeit prüfen

The Human CD38 Monoclonal Antibody Daratumumab Shows Antitumor Activity and Hampers Leukemia-Microenvironment Interactions in Chronic Lymphocytic Leukemia

Clinical cancer research, 2017-03, Vol.23 (6), p.1493-1505

2017

Link zum Volltext

Verfügbarkeit prüfen

ON 01910.Na is selectively cytotoxic for chronic lymphocytic leukemia cells through a dual mechanism of action involving PI3K/AKT inhibition and induction of oxidative stress

Clinical cancer research, 2012-04, Vol.18 (7), p.1979-1991

2012

Link zum Volltext

Verfügbarkeit prüfen

Treatment-Induced Oxidative Stress and Cellular Antioxidant Capacity Determine Response to Bortezomib in Mantle Cell Lymphoma

Clinical cancer research, 2011-08, Vol.17 (15), p.5101-5112

2011

Link zum Volltext

Verfügbarkeit prüfen

Schedule-Dependent Synergy between the Heat Shock Protein 90 Inhibitor 17-(Dimethylaminoethylamino)-17-Demethoxygeldanamycin and Doxorubicin Restores Apoptosis to p53-Mutant Lymphoma Cell Lines

Clinical cancer research, 2006-11, Vol.12 (21), p.6547-6556

2006

Link zum Volltext

Verfügbarkeit prüfen

Treatment with Ibrutinib Inhibits BTK- and VLA-4-Dependent Adhesion of Chronic Lymphocytic Leukemia Cells In Vivo

Clinical cancer research, 2015-10, Vol.21 (20), p.4642-4651

2015

Link zum Volltext

Verfügbarkeit prüfen

Clinical Outcomes in Patients with Multi-Hit TP53 Chronic Lymphocytic Leukemia Treated with Ibrutinib

Clinical cancer research, 2021-08, Vol.27 (16), p.4531-4538

2021

Link zum Volltext

Verfügbarkeit prüfen

Select Antitumor Cytotoxic CD8 + T Clonotypes Expand in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib

Clinical cancer research, 2021-08, Vol.27 (16), p.4624-4633

2021

Link zum Volltext

Verfügbarkeit prüfen

Pharmacodynamic Analysis of BTK Inhibition in Patients with Chronic Lymphocytic Leukemia Treated with Acalabrutinib

Clinical cancer research, 2020-06, Vol.26 (12), p.2800-2809

2020

Link zum Volltext

Verfügbarkeit prüfen

B-cell Receptor Pathway Mutations Are Infrequent in Patients with Chronic Lymphocytic Leukemia on Continuous Ibrutinib Therapy

Clinical cancer research, 2023-08, Vol.29 (16), p.3065

2023

Link zum Volltext

Verfügbarkeit prüfen

CD49d Expression Identifies a Biologically Distinct Subtype of Chronic Lymphocytic Leukemia with Inferior Progression-Free Survival on BTK Inhibitor Therapy

Clinical cancer research, 2023-09, Vol.29 (18), p.3612

2023

Link zum Volltext

Verfügbarkeit prüfen

SOX11 Inhibitors Are Cytotoxic in Mantle Cell Lymphoma

Clinical cancer research, 2021-08, Vol.27 (16), p.4652-4663

2021

Link zum Volltext

Verfügbarkeit prüfen

Ibrutinib Inhibits VLA-4-Dependent Adhesion in CLL-Reply

Clinical cancer research, 2016-07, Vol.22 (13), p.3412-3412

2016

Link zum Volltext

Verfügbarkeit prüfen

Autoreactive, Cytotoxic T Lymphocytes Specific for Peptides Derived from Normal B-Cell Differentiation Antigens in Healthy Individuals and Patients with B-Cell Malignancies

Clinical cancer research, 2004-02, Vol.10 (3), p.1047-1056

2004

Link zum Volltext

Verfügbarkeit prüfen

microRNA expression profiles identify subtypes of mantle cell lymphoma with different clinicobiological characteristics

Clinical cancer research, 2013-06, Vol.19 (12), p.3121-3129

2013

Link zum Volltext

Verfügbarkeit prüfen

The Bruton’s tyrosine kinase (BTK) inhibitor acalabrutinib demonstrates potent on-target effects and efficacy in two mouse models of chronic lymphocytic leukemia

Clinical cancer research, 2016-11, Vol.23 (11), p.2831-2841

2016

Link zum Volltext

Verfügbarkeit prüfen

The human CD38 monoclonal antibody daratumumab shows anti-tumor activity and hampers leukemia-microenvironment interactions in chronic lymphocytic leukemia

Clinical cancer research, 2016-09, Vol.23 (6), p.1493-1505

2016

Link zum Volltext

Verfügbarkeit prüfen

Disruption of in vivo chronic lymphocytic leukemia tumor-microenvironment interactions by ibrutinib – findings from an investigator initiated phase 2 study

Clinical cancer research, 2015-12, Vol.22 (7), p.1572-1582

2015

Link zum Volltext

Verfügbarkeit prüfen

ON 01910.Na Is Selectively Cytotoxic for Chronic Lymphocytic Leukemia Cells through a Dual Mechanism of Action Involving P13K/AKT Inhibition and Induction of Oxidative Stress

Clinical cancer research, 2012, Vol.18 (7), p.1979-1991

2012

Link zum Volltext

Verfügbarkeit prüfen

1 – 23 von 23

Suche als RSS-Feed

Aktive Filter

Zeitschrift / SerieClinical Cancer Research

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(23)
Mit Volltextzugriff
(21)

Publikationsform

Artikel
(23)

Sprache

Englisch
(23)
Japanisch
(6)

Erscheinungsjahr

n.n

Kollektion

EZB Free E-Journals
(23)
NUS Single-Journal Subscriptions
(23)

Menü

Weitere Dienste

Einstellungen

The Bruton Tyrosine Kinase (BTK) Inhibitor Acalabrutinib Demonstrates Potent On-Target Effects and Efficacy in Two Mouse Models of Chronic Lymphocytic Leukemia

Disruption of in vivo Chronic Lymphocytic Leukemia Tumor-Microenvironment Interactions by Ibrutinib--Findings from an Investigator-Initiated Phase II Study

Interactions between Ibrutinib and Anti-CD20 Antibodies: Competing Effects on the Outcome of Combination Therapy

Combined BTK and PI3Kδ Inhibition with Acalabrutinib and ACP-319 Improves Survival and Tumor Control in CLL Mouse Model

Unique Cell Surface Expression of Receptor Tyrosine Kinase ROR1 in Human B-Cell Chronic Lymphocytic Leukemia

The Human CD38 Monoclonal Antibody Daratumumab Shows Antitumor Activity and Hampers Leukemia-Microenvironment Interactions in Chronic Lymphocytic Leukemia

ON 01910.Na is selectively cytotoxic for chronic lymphocytic leukemia cells through a dual mechanism of action involving PI3K/AKT inhibition and induction of oxidative stress

Treatment-Induced Oxidative Stress and Cellular Antioxidant Capacity Determine Response to Bortezomib in Mantle Cell Lymphoma

Schedule-Dependent Synergy between the Heat Shock Protein 90 Inhibitor 17-(Dimethylaminoethylamino)-17-Demethoxygeldanamycin and Doxorubicin Restores Apoptosis to p53-Mutant Lymphoma Cell Lines

Treatment with Ibrutinib Inhibits BTK- and VLA-4-Dependent Adhesion of Chronic Lymphocytic Leukemia Cells In Vivo

Clinical Outcomes in Patients with Multi-Hit TP53 Chronic Lymphocytic Leukemia Treated with Ibrutinib

Select Antitumor Cytotoxic CD8 + T Clonotypes Expand in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib

Pharmacodynamic Analysis of BTK Inhibition in Patients with Chronic Lymphocytic Leukemia Treated with Acalabrutinib

B-cell Receptor Pathway Mutations Are Infrequent in Patients with Chronic Lymphocytic Leukemia on Continuous Ibrutinib Therapy

CD49d Expression Identifies a Biologically Distinct Subtype of Chronic Lymphocytic Leukemia with Inferior Progression-Free Survival on BTK Inhibitor Therapy

SOX11 Inhibitors Are Cytotoxic in Mantle Cell Lymphoma

Ibrutinib Inhibits VLA-4-Dependent Adhesion in CLL-Reply

Autoreactive, Cytotoxic T Lymphocytes Specific for Peptides Derived from Normal B-Cell Differentiation Antigens in Healthy Individuals and Patients with B-Cell Malignancies

microRNA expression profiles identify subtypes of mantle cell lymphoma with different clinicobiological characteristics

The Bruton’s tyrosine kinase (BTK) inhibitor acalabrutinib demonstrates potent on-target effects and efficacy in two mouse models of chronic lymphocytic leukemia

The human CD38 monoclonal antibody daratumumab shows anti-tumor activity and hampers leukemia-microenvironment interactions in chronic lymphocytic leukemia

Disruption of in vivo chronic lymphocytic leukemia tumor-microenvironment interactions by ibrutinib – findings from an investigator initiated phase 2 study

ON 01910.Na Is Selectively Cytotoxic for Chronic Lymphocytic Leukemia Cells through a Dual Mechanism of Action Involving P13K/AKT Inhibition and Induction of Oxidative Stress

Aktive Filter

Suchergebnisse filtern